26 November 2021 - Rholistiq is Kadmon's first product to be approved in Australia.

The TGA has belumosudil mesilate (Rholistiq) for the treatment of patients with chronic graft-versus-host disease (chronic GVHD) aged 12 years and older who have an inadequate response to corticosteroids.

Read TGA prescription medicine decision summary for Rholistiq